Emergent BioSolutions Inc (EBS)
10.09
-0.19
(-1.85%)
USD |
NYSE |
Jan 08, 16:00
9.91
-0.18
(-1.78%)
After-Hours: 20:00
Emergent BioSolutions SG&A Expense (Quarterly): 76.60M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Abbott Laboratories | 2.895B |
| Tonix Pharmaceuticals Holding Corp | 7.707M |
| Chimerix Inc | 5.173M |
| Marinus Pharmaceuticals Inc | 12.57M |
| MAIA Biotechnology Inc | 1.521M |